Virology & Mycology
Open Access
ISSN: 2161-0517
ISSN: 2161-0517
Jamal Hashemi, F Mohammadi, M R Velashjerdifarahani, S M Seyedmousavi and S J Hashemi
Tehran University of Medical Sciences, Iran
Hamedan University of Medical Sciences, Iran
Erasmus University Medical Centre, Netherlands
Posters & Accepted Abstracts: Virol Mycol
Background: Aspergillus fumigatusis a major cause of allergic syndromes, aspergilloma and life threatening invasive infections in immunocompromised hosts. To date, a wide range of mutations in A. fumigates have been described conferring azoleresistance, which commonly involves modifications in the cyp51A-gene (substitutions at codons G54, G138, P216, F219, M220, G448 and specifically codon L98 in combination with a 34-bp tandem repeat in the promoter region of the gene), the target for azole antifungals. Aim: We investigated the prevalence of azole-resistance in clinical A. fumigatus isolates obtained from patients in Iran during 2010 to 2014. Methods: 172 clinical A. fumigatus isolates obtained from patients underlying invasive pulmonary aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis and aspergilloma, were investigated for the antifungal activity of itraconazole, voriconazole and posaconazole using a broth microdilution test, according to EUCAST reference method. All isolates were confirmed by amplification of amplification of the tubulin gene. Results: Of the 172 A. fumigates isolates tested during 2010 to 2014, 6 (3.5%) had high MIC values of itraconazole (>16 mg/L) and voriconazole (ΓΆΒ?Β¥4 mg/L). All 6 isolates showed a multi-resistant phenotype with high MICs of ITC and VRC. Conclusion: We report azole-resistant among clinical isolates of Aspergillus fumigates in Iran over the recent 5 years (2010 to 2014). Azole resistance wide-spread and emerging and international surveillance is warranted.
Email: sjhashemi@tums.ac.ir